doxorubicin at antigen release, addressing threshold drift
doxorubicin (immunogenic chemotherapy) acts at the antigen release step of the cancer-immunity cycle. The failure mode is threshold drift: threshold moves out of reach of normal loading current. Capacitor sometimes fires, sometimes doesn't; unpredictable activation.
What this is
The Living Scorecard is Encounter's open record of structural predictions. Each hypothesis names a candidate intervention, where in the cycle it is predicted to act, the failure mode it is predicted to address, and the evidence available when the prediction was made.
Predictions are locked with timestamps before they can be tested. Encounter generates them daily, many more than any one person can chase, so the field can see what the framework claims structurally, ahead of the data. Some will hold. Some will be refuted. Both stay on the page. The point is that each prediction is committed before the answer is known, so the data that arrives later can confirm or refute it.
Structural argument
At the antigen release step of the cancer-immunity cycle (capacitor regime, position P1), doxorubicin acts via immunogenic chemotherapy. The failure mode is threshold drift: threshold moves out of reach of normal loading current. Capacitor sometimes fires, sometimes doesn't; unpredictable activation. The intervention's regime-type class lines up with the position's regime, and failure_threshold_drift belongs to that regime's failure set.
rule_r13(required) — Combinatorial candidate is grounded in R13's position-to-state table, which determines which interventions are structurally addressable at which positions.
Substrate
- Domain
- domain_cellular_biology
- Cycle
- cycle_l4_canonical
- Position(s)
- position_p1
- Failure modes
- failure_threshold_drift
Evidence at generation
"doxorubicin" AND "cancer immunotherapy"
- PMID 38971175
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
- PMID 37391428
Ultrasound-responsive low-dose doxorubicin liposomes trigger mitochondrial DNA release and activate cGAS-STING-mediated antitumour immunity.
- PMID 35303868
Doxorubicin and CpG loaded liposomal spherical nucleic acid for enhanced Cancer treatment.
- PMID 25634491
Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer.
- PMID 38481326
Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
Targets: —
doxorubicin cancer immunotherapy
- NCT07227584
Acute Lymphoblastic Leukemia
Primary: Treatment Completion Rate Through Time Point 3 (TP3)
- NCT03937830
Hepatocellular Cancer
Primary: To evaluate the 6-month progression free survival (PFS) in participants with advanced HCC BCLC stage B treated with bevacizumab, durvalumab, tremelimumab and TACE
- NCT04433221
Sarcoma
Primary: Safety of CART cells infusion
- NCT04221035
High-Risk Neuroblastoma
Primary: Event free survival (EFS)
- NCT00004197
Lymphoma
Status timeline
- Draft2026-05-28T23:27:38Z
Generated by combinatorial walker (v0.1.1; verb_target-aware, sub-regime failures). Awaiting operator review for the daily top-5 batch.
by system
- Published2026-05-29T06:35:42Z
Published as part of the first 5-hypothesis daily batch. Engine v0.1.1: verb_target-aware combinatorial walker, sub-regime failure pool, lowercase evidence queries. Operator review pass: kept as-is.
by raimo